Clone:
REA1006
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MC
Alternative names:
KIR2DL2, KIR2DL3, KIR2DS2

Extended validation for CD158b (KIR2DL2/DL3) Antibody, anti-human, REAfinity™

Specificity

Other clonesOverlap in epitope recognition with REA1006
DX27++
HP-3E4-
CH-L+
NKVFS1++
Cells were incubated with an excess of purified unconjugated CD158b (KIR2DL2/DL3) (REA1006) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD158b (KIR2DL2/DL3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158b (KIR2DL2/DL3) antibodies and with a suitable counterstaining. As a control, CD158b (KIR2DL2/DL3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD158b (KIR2DL2/DL3) (REA1006). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD158b (KIR2DL2/DL3) (REA1006). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD158b (KIR2DL2/DL3) (REA1006). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD158b (KIR2DL2/DL3) (REA1006). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD158b (KIR2DL2/DL3) (REA1006). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD158b (KIR2DL2/DL3) Antibody, anti-human, REAfinity™

Overview

Clone REA1006 recognizes the human CD158b1 (KIR2DL2), CD158b2 (KIR2DL3), and CD158j (KIR2DS2) antigens, members of the killer immunoglobulin-like receptor (KIR) family expressed on natural killer (NK) cells and subsets of T cells.
KIRs contribute to the regulation of NK cell–mediated cytotoxicity and possess high allelic polymorphism with either 2 or 3 Ig-like extracellular domains. According to the length of their cytoplasmic tail, KIRs can be further subdivided in inhibitory KIRs (KIR2DL or KIR3DL) and activating KIRs (KIR2DS or KIR3DS). CD158b provides an inhibitory signal on NK cell lytic activity upon interaction with HLA C (e.g. alleles HLA-Cw1, HLA-Cw3, HLA-Cw7) in an antigen-independent manner.
Additional information: Clone REA1006 displays negligible binding to Fc receptors.

Alternative names

KIR2DL2, KIR2DL3, KIR2DS2

Detailed product information

Technical specifications

CloneREA1006
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD158b (KIR2DL2/DL3)
Alternative names of antigenKIR2DL2, KIR2DL3, KIR2DS2
Molecular mass of antigen [kDa]36
Distribution of antigenNK cells, T cells
Entrez Gene ID3803, 3804
RRIDAB_2727782, AB_2727709, AB_2727783, AB_2727710, AB_2727711, AB_2727784, AB_2727712, AB_2727785, AB_2727713, AB_2819419

Resources for CD158b (KIR2DL2/DL3) Antibody, anti-human, REAfinity™

Documents and Protocols

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD158b (KIR2DL2/DL3) Antibody, anti-human, REAfinity™

Publications

  1. Selvakumar, A. et al. (1997) Polymorphism and domain variability of human killer cell inhibitory receptors. Immunol. Rev. 155: 183-196
  2. Farag, S. S. et al. (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukaemia effect. Blood 100(6): 1935-1947
  3. Hsu, K. et al. (2002) The killer cell immunoglobin-like (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol. Rev. 190: 40-52

Related products for
CD158b (KIR2DL2/DL3) Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?